Abstract 52P
Background
Chimeric antigen receptor T cells (CAR Ts) have shown limited efficacy in solid tumors due to poor penetration, constrained activity, and early exhaustion into the immunosuppressive tumor microenvironment (TME). While stimulatory cytokines can counteract immune suppression, their systemic administration entails risk of toxicities and counter-regulatory responses.
Methods
Here, we leveraged a population of tumor-associated TIE2 expressing macrophages (TEMs) to specifically release interferon-a (IFN) and/or orthogonal interleukin-2 (oIL2) in the TME through a hematopoietic stem cell-based gene therapy to broadly reprogram it toward immune activation. To investigate whether TME reprogramming could favor CAR-T function in hostile conditions, we took advantage of immunocompetent mice orthotopically challenged with a novel high-grade glioma (HGG) model (mGB2), faithfully recapitulating the human disease. We generated CAR Ts, either bearing an orthogonal IL-2 receptor or not, by optimizing a high-efficiency lentiviral-based transduction protocol of murine T cells.
Results
Targeted cytokine delivery rescued CAR Ts functionality against the clinically relevant antigen B7H3 in the mGB2 model which was refractory to CAR Ts alone. Immunophenotypic and transcriptomic analyses at single-cell resolution showed inhibition of CAR-T premature terminal exhaustion and induction of effector/memory states featuring activation of signaling pathways and transcriptional networks putatively boosting anti-tumor activity, resulting in tumor growth inhibition and survival prolongation. Importantly, IFN, especially when combined with private oIL2 signaling to CAR Ts, also engaged an endogenous T cell response spreading to tumor-associated antigens beyond B7H3. This accounted for rejection of B7H3KO mGB2 rechallenge in mice that cleared the primary tumor.
Conclusions
Overall, the rescued CAR and endogenous T cell function delayed HGG growth and prolonged mice survival, suggesting that the combination of the above two gene and cell therapies, which are already under clinical testing as monotherapies, could achieve synergistic effects also in HGG patients.
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro; Louis-Jeantet Foundation through the 2019 Jeantet-Collen Prize for Translational Medicine.
Disclosure
B. Gentner, L. Naldini: Financial Interests, Personal, Ownership Interest: Genenta science. All other authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract